Medicinal Genomics’ PathoSEEK® platform has more cannabis matrices accredited for Aspergillus, Salmonella, and STEC E. coli than any other solution on the market today.
Beverly, MA. — Medicinal Genomics Corp. (MGC), a pioneer in harnessing cannabis genomics to improve agricultural productivity, safety, and transparency, today announced that AOAC International has approved the company’s PathoSEEK® Salmonella and STEC E. coli Multiplex Assay with SenSATIVAx® Extraction Kits to simultaneously detect Salmonella spp. and Escherichia coli carrying Shiga toxin 1 and/or 2 (stx1 and/or stx2) in a single qPCR reaction for cannabis flower, cannabis concentrates, and THC-infused chocolates using the Agilent Technologies AriaMx and the BioRad CFx-96 instruments.
MGC’s PathoSEEK® platform has more cannabis matrices accredited for Aspergillus, Salmonella, and STEC E. coli than any other solution on the market today. As with all other MGC’s certifications, this latest was validated according to the AOAC Performance Tested MethodSM Program and awarded certification number PTM 022202. The evaluation consisted of PTM Program parameters such as robustness, product consistency, stability, inclusivity & exclusivity, and matrix studies.
MGC’s PathoSEEK® Microbial Safety Testing Platform utilizes a novel, qPCR-based assay, and an internal plant DNA control for every reaction. This assay involves a simple two-step protocol that is both flexible and automation compatible. Unlike other techniques, this multiplexing strategy verifies the performance of the assay when detecting pathogens, which minimizes false negative results due to reaction set-up errors or failing experimental conditions.
“AOAC’s validation of our Salmonella/STEC E. coli assay across the various cannabis matrices is further proof of our platform’s robustness and versatility,” said Dr. Sherman Hom, MGC’s Director of Regulatory Affairs. “We are excited that our PathoSEEK® platform is moving in concert with the FDA’s new blueprint to improve food safety by modernizing the regulatory framework, while leveraging the use of proven molecular tools to accelerate predictive capabilities, enhance prevention, and enhance our ability to swiftly adapt to pathogen outbreaks that could impact consumer safety.”
AOAC INTERNATIONAL is a global standardization organization that certifies analytical test methods. The AOAC Performance Tested Methods℠ designation is recognized by the US Department of Agriculture, the Food and Drug Administration, and global regulatory agencies. Visit AOAC’s website to learn more about their certification process.
About Medicinal Genomics Corporation
Medicinal Genomics Corporation is a pioneer in advancing the genomics of cannabis to build a stronger scientific foundation for cannabis-based products. The company’s unmatched expertise in genetic science help cultivators, dispensaries, and testing laboratories characterize and understand the quality and consistency of cannabis to ensure patients and consumers have access to consistently safe high-quality cannabis. To support their mission, Medicinal Genomics also produces CannMed, an annual gathering of cannabis leaders dedicated to the scientific advancement of the cannabis industry; and Kannapedia, the world’s most complete public cannabis cultivar database. For more information, please visit www.medicinalgenomics.com.
MGC media contact: